TuHURA

TuHURA Biosciences, Inc. is a Phase 3 registrational-stage immuno-oncology company dedicated to developing new technologies to overcome resistance to cancer immunotherapy. The company's technology aims to address both primary and acquired resistance to checkpoint inhibitors or cell therapies in cancer treatment.TuHURA's Immune Fx™ (IFx™) personalized cancer vaccine technology is designed to "trick" the body’s immune system into attacking tumor cells by making tumor cells appear like bacteria, leveraging natural mechanisms conserved throughout evolution to harness the power of the innate immune response for recognizing threats from foreign pathogens such as bacteria or viruses. TuHURA’s personalized cancer vaccines can target tumors via intratumoral injection using the company’s pDNA vaccine or intravenously using its mRNA vaccine.TuHURA is utilizing its Delta Receptor technology to develop first-in-class bifunctional antibody-drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs) to inhibit their immunosuppressive effects on the tumor microenvironment, prevent T-cell exhaustion, and counteract resistance to checkpoint inhibitors and cell therapies. The company’s Delta Receptor technology was developed at Moffitt Cancer Center, West Virginia University, and TuHURA Biopharma.